Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.

Rui-Hua XuYang ZhangHong-Yun ZhaoWen-Feng FangHui-Yan LuoMiao-Zhen QiuMing-Ming HeBen-Yan ZouJie XieChun-Lei JinXian-Feng ZhouFeng WangFeng-Hua WangYu-Hong LiZhi-Qiang WangRui-Hua Xu

Published in: The oncologist (2022)

SHR7390 0.5 mg plus camrelizumab showed a manageable safety profile. Preliminary clinical activity was reported regardless of MSI and BRAF status.

Keyphrases

randomized controlled trial
clinical trial
combination therapy
study protocol
wild type